PACIRA BIOSCIENCES INC (PCRX) Stock Fundamental Analysis
NASDAQ:PCRX • US6951271005
22.645 USD
-0.57 (-2.48%)
Last: Feb 23, 2026, 09:56 AM
Taking everything into account, PCRX scores 6 out of 10 in our fundamental rating. PCRX was compared to 192 industry peers in the Pharmaceuticals industry. PCRX scores excellent on profitability, but there are some minor concerns on its financial health. PCRX is valued quite cheap, but it does not seem to be growing. This makes PCRX very considerable for value investing!
1. Profitability
1.1 Basic Checks
- In the past year PCRX was profitable.
- In the past year PCRX had a positive cash flow from operations.
- PCRX had positive earnings in 4 of the past 5 years.
- PCRX had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- The Return On Assets of PCRX (1.65%) is better than 81.25% of its industry peers.
- PCRX has a better Return On Equity (2.95%) than 82.29% of its industry peers.
- PCRX's Return On Invested Capital of 3.63% is amongst the best of the industry. PCRX outperforms 82.29% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for PCRX is significantly below the industry average of 12.95%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROIC | 3.63% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
1.3 Margins
- PCRX's Profit Margin of 2.99% is amongst the best of the industry. PCRX outperforms 80.73% of its industry peers.
- PCRX's Operating Margin of 8.88% is amongst the best of the industry. PCRX outperforms 81.25% of its industry peers.
- PCRX's Operating Margin has improved in the last couple of years.
- PCRX has a better Gross Margin (79.17%) than 84.90% of its industry peers.
- PCRX's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% |
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PCRX is destroying value.
- Compared to 1 year ago, PCRX has less shares outstanding
- Compared to 5 years ago, PCRX has more shares outstanding
- Compared to 1 year ago, PCRX has a worse debt to assets ratio.
2.2 Solvency
- PCRX has an Altman-Z score of 1.92. This is not the best score and indicates that PCRX is in the grey zone with still only limited risk for bankruptcy at the moment.
- PCRX's Altman-Z score of 1.92 is fine compared to the rest of the industry. PCRX outperforms 62.50% of its industry peers.
- The Debt to FCF ratio of PCRX is 3.03, which is a good value as it means it would take PCRX, 3.03 years of fcf income to pay off all of its debts.
- PCRX's Debt to FCF ratio of 3.03 is amongst the best of the industry. PCRX outperforms 91.67% of its industry peers.
- PCRX has a Debt/Equity ratio of 0.52. This is a neutral value indicating PCRX is somewhat dependend on debt financing.
- PCRX has a worse Debt to Equity ratio (0.52) than 61.98% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Altman-Z | 1.92 |
ROIC/WACC0.46
WACC7.86%
2.3 Liquidity
- PCRX has a Current Ratio of 5.26. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
- The Current ratio of PCRX (5.26) is better than 65.10% of its industry peers.
- PCRX has a Quick Ratio of 3.78. This indicates that PCRX is financially healthy and has no problem in meeting its short term obligations.
- With a Quick ratio value of 3.78, PCRX perfoms like the industry average, outperforming 59.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 |
3. Growth
3.1 Past
- The earnings per share for PCRX have decreased by -6.90% in the last year.
- The Earnings Per Share has been growing by 13.96% on average over the past years. This is quite good.
- The Revenue for PCRX has decreased by -16.85% in the past year. This is quite bad
- The Revenue has been growing by 10.73% on average over the past years. This is quite good.
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
3.2 Future
- The Earnings Per Share is expected to grow by 7.01% on average over the next years.
- PCRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.79% yearly.
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.79%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- PCRX is valuated cheaply with a Price/Earnings ratio of 7.62.
- Compared to the rest of the industry, the Price/Earnings ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 94.27% of the companies listed in the same industry.
- PCRX is valuated cheaply when we compare the Price/Earnings ratio to 26.99, which is the current average of the S&P500 Index.
- The Price/Forward Earnings ratio is 6.52, which indicates a rather cheap valuation of PCRX.
- 93.75% of the companies in the same industry are more expensive than PCRX, based on the Price/Forward Earnings ratio.
- PCRX is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.02, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.62 | ||
| Fwd PE | 6.52 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, PCRX is valued cheaper than 95.31% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of PCRX indicates a rather cheap valuation: PCRX is cheaper than 94.27% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 7.49 | ||
| EV/EBITDA | 6.38 |
4.3 Compensation for Growth
- PCRX has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.55
EPS Next 2Y4.05%
EPS Next 3Y6.92%
5. Dividend
5.1 Amount
- No dividends for PCRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
NASDAQ:PCRX (2/23/2026, 9:56:58 AM)
22.645
-0.57 (-2.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)02-26 2026-02-26/amc
Inst Owners114.44%
Inst Owner Change-2.99%
Ins Owners0.79%
Ins Owner Change16.54%
Market Cap930.71M
Revenue(TTM)716.79M
Net Income(TTM)21.44M
Analysts76.92
Price Target30.31 (33.85%)
Short Float %19.55%
Short Ratio8.74
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)3.71%
Min EPS beat(2)2.13%
Max EPS beat(2)5.28%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)1.99%
Max EPS beat(4)6.81%
EPS beat(8)6
Avg EPS beat(8)5.89%
EPS beat(12)7
Avg EPS beat(12)1.4%
EPS beat(16)8
Avg EPS beat(16)-3.85%
Revenue beat(2)0
Avg Revenue beat(2)-3.29%
Min Revenue beat(2)-3.59%
Max Revenue beat(2)-2.99%
Revenue beat(4)0
Avg Revenue beat(4)-3.23%
Min Revenue beat(4)-5.92%
Max Revenue beat(4)-0.42%
Revenue beat(8)1
Avg Revenue beat(8)-2.14%
Revenue beat(12)1
Avg Revenue beat(12)-2.68%
Revenue beat(16)1
Avg Revenue beat(16)-2.53%
PT rev (1m)0%
PT rev (3m)-19.69%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.75%
EPS NY rev (1m)0%
EPS NY rev (3m)2.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.11%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.99%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.62 | ||
| Fwd PE | 6.52 | ||
| P/S | 1.3 | ||
| P/FCF | 7.49 | ||
| P/OCF | 6.58 | ||
| P/B | 1.28 | ||
| P/tB | 2.87 | ||
| EV/EBITDA | 6.38 |
EPS(TTM)2.97
EY13.12%
EPS(NY)3.48
Fwd EY15.35%
FCF(TTM)3.02
FCFY13.35%
OCF(TTM)3.44
OCFY15.2%
SpS17.44
BVpS17.69
TBVpS7.9
PEG (NY)N/A
PEG (5Y)0.55
Graham Number34.39
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.65% | ||
| ROE | 2.95% | ||
| ROCE | 5.34% | ||
| ROIC | 3.63% | ||
| ROICexc | 4.58% | ||
| ROICexgc | 7.99% | ||
| OM | 8.88% | ||
| PM (TTM) | 2.99% | ||
| GM | 79.17% | ||
| FCFM | 17.33% |
ROA(3y)-0.93%
ROA(5y)2.13%
ROE(3y)-1.97%
ROE(5y)4.66%
ROIC(3y)4.3%
ROIC(5y)4.55%
ROICexc(3y)6.05%
ROICexc(5y)7.29%
ROICexgc(3y)13.64%
ROICexgc(5y)24.93%
ROCE(3y)6.32%
ROCE(5y)6.69%
ROICexgc growth 3Y-33.29%
ROICexgc growth 5Y14.33%
ROICexc growth 3Y-3.13%
ROICexc growth 5Y10.2%
OM growth 3Y-15.96%
OM growth 5Y11.41%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.7%
GM growth 5Y0.27%
F-Score7
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.52 | ||
| Debt/FCF | 3.03 | ||
| Debt/EBITDA | 2.44 | ||
| Cap/Depr | 18.95% | ||
| Cap/Sales | 2.4% | ||
| Interest Coverage | 4.07 | ||
| Cash Conversion | 91.52% | ||
| Profit Quality | 579.36% | ||
| Current Ratio | 5.26 | ||
| Quick Ratio | 3.78 | ||
| Altman-Z | 1.92 |
F-Score7
WACC7.86%
ROIC/WACC0.46
Cap/Depr(3y)22.15%
Cap/Depr(5y)83.49%
Cap/Sales(3y)2.76%
Cap/Sales(5y)5.11%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-6.9%
EPS 3Y2.39%
EPS 5Y13.96%
EPS Q2Q%-11.39%
EPS Next Y-6.13%
EPS Next 2Y4.05%
EPS Next 3Y6.92%
EPS Next 5Y7.01%
Revenue 1Y (TTM)-16.85%
Revenue growth 3Y8.98%
Revenue growth 5Y10.73%
Sales Q2Q%6.49%
Revenue Next Year4.33%
Revenue Next 2Y6.28%
Revenue Next 3Y7.3%
Revenue Next 5Y6.79%
EBIT growth 1Y-45.68%
EBIT growth 3Y-8.41%
EBIT growth 5Y23.37%
EBIT Next Year1.3%
EBIT Next 3Y6.32%
EBIT Next 5Y6.85%
FCF growth 1Y-4.68%
FCF growth 3Y30.84%
FCF growth 5Y24.28%
OCF growth 1Y-5.2%
OCF growth 3Y14.64%
OCF growth 5Y21.85%
PACIRA BIOSCIENCES INC / PCRX FAQ
What is the ChartMill fundamental rating of PACIRA BIOSCIENCES INC (PCRX) stock?
ChartMill assigns a fundamental rating of 6 / 10 to PCRX.
What is the valuation status for PCRX stock?
ChartMill assigns a valuation rating of 8 / 10 to PACIRA BIOSCIENCES INC (PCRX). This can be considered as Undervalued.
How profitable is PACIRA BIOSCIENCES INC (PCRX) stock?
PACIRA BIOSCIENCES INC (PCRX) has a profitability rating of 7 / 10.
What is the valuation of PACIRA BIOSCIENCES INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for PACIRA BIOSCIENCES INC (PCRX) is 7.62 and the Price/Book (PB) ratio is 1.28.